Vitamin D supplementation for early-stage CLL is associated with prolonged TTFT and TFI

Tamar Tadmor, MD, Bnai Zion Medical Center, Haifa, Israel, presents a study examining the impact of vitamin D supplementation on patients with chronic lymphocytic leukemia (CLL) who are not currently undergoing treatment. The study reveals that vitamin D supplements extend both the time to first treatment (TTFT) and treatment-free interval (TFI), indicating a beneficial proactive strategy for untreated patients. However, confirmation of these findings awaits a prospective trial. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.